Table 3. Correlation of PLK3 expression with several clinicopathological factors.
| All cases | PLK3 negative (IRS 0-6) | PLK3 positive (IRS 7-12) | P-value | |
|---|---|---|---|---|
| Age | ||||
| <60 years | 42 (54.5%) | 22 (52.4%) | 20 (47.6%) | 0.649+ |
| >60 years | 35 (45.5%) | 16 (45.7%) | 19 (54.3%) | |
| FIGO stage | ||||
| I | 17 (22.1%) | 9 (52.9%) | 8(47.1%) | |
| II | 9 (11.7%) | 5 (55.6%) | 4 (44.4%) | 0.289* |
| III | 46 (59.7%) | 24 (52.2%) | 22 (47.8%) | |
| IV | 5 (6.5%) | 0 (0%) | 5 (100%) | |
| Grade | ||||
| G1 | 15 (19.5%) | 12 (80%) | 3 (20%) | |
| G2 | 33 (42.9%) | 14 (42.4%) | 19 (57.6%) | 0.025* |
| G3 | 29 (37.6%) | 12 (41.4%) | 17 (58.6%) | |
+
Fisher's exact test.
*
χ2 test for trends. PLK=Polo-like kinase; IRS=immunoreactivity-scoring system.